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Abstract 
Alendronate sodium, a bisphosphonate drug, is used to treat osteoporosis and other bone 
diseases. The present study was designed to conduct comparative bioavailability analysis of oral 
formulations of alendronate sodium through an open-label, randomized, 2-sequence, 2-period 
crossover study. Healthy adult male Pakistani volunteers received a single 70mg dose of the test 
or reference formulation of alendronate sodium followed by a 7 day washout period. Plasma 
drug concentrations were determined using a validated HPLC-post column fluorescence 
derivatization method. AUC0-t, AUC0-, Cmax and Tmax were determined by non-compartmental 
analysis and were found within the permitted range of 80% to 125% set by the US Food and 
Drug Administration (FDA). Results show that both in vitro and in vivo assays of all test brands 
were within the specification of the US Pharmacopoeial limits and were statistically 
bioequivalent. No adverse events were reported in this study.  
Key words: Alendronate, bioavailability, bioequivalence, pharmacokinetic parameters, HPLC   
Abbreviations: PK-Pharmacokinetic parameter, Cmax -maximum plasma concentration, Tmax -
time to reach maximum plasma concentration, AUC-area under curve, t1/2-half life, ke-
elimination rate constant. 
1. Introduction  
In recent years, the provision of quality health care is receiving global interest and medicines 
have become a core component of health care system to cater health care needs of patients (1-3). 
In some countries, up to 60% of total health care expenditure is allocated to the cost of medicines 
(4) which can be controlled with rational and judicious use of medicines. An essential cost 
reduction measure is to encourage the prescription of low-cost generics. The generic drugs have 
captured more than 65% of the global pharmaceutical market (5, 6). Average prescription 
spending in the United States topped 286 billion in 2007, prompting calls for greater generic 
drug use to reduce costs without sacrificing quality. Generic drugs account for 66% of 
prescriptions filled in the US but less than 13% of the cost (7). The importance of generic drugs 
in health care has made it crucial to consistently monitor their pharmaceutical quality and in-vivo 
performance since these are alternative to innovator products in the market (8). Alendronate 
sodium (sodium [4-amino-1-hydroxybutylidene] bisphosphonate) is prescribed for the 
management of bone diseases such as RVWHRSRURVLV K\SHUFDOFHPLD DQG 3DJHW¶V GLVHDVH (9). 
Alendronic acid is released immediately in solution and irritate mucosal lining during 
deglutition. As a consequence, it can cause esophagitis. Thus, it is administered orally as tablets 
in its monosodium salt form to prevent esophagitis (10, 11). Moreover, it should be taken in 
morning with a glass of water at least 30min before food and the patient should avoid lying down 
during that time.. The fast release of alendronic acid exhibits a potential health risk, which 
should be kept as low as possible (12). 
Alendronate sodium is selectively accumulated in the bone, and its oral absorption is <1% of the 
administered dose in the fasted state (13). It is reported that about 40% of an oral dose is 
excreted within 8-12 hours, while the remaining is gradually released from the bone, depending 
on the rate of bone turnover, and is eventually eliminated in the urine (14). It is an effective 
inhibitor of osteoclast and bone resorption. The plasma half-life of alendronate is 1.7-1.8 hours 
in healthy individuals (13, 14, 15). An increasing number of generic alendronate formulations 
have become available. Although expected to have the same tolerability and efficacy, head-to 
head comparison of generic and brand alendronate was never performed. A study compared the 
tolerability and efficacy of generic and brand alendronate and found no significant differences in 
overall tolerance between treatment groups (16). It was also found that the level of bone turnover 
markers were significantly decreased over 12 weeks of follow-up for generic and branded 
alendronate. Generic caused significantly higher abdominal pain scores. Therefore, generic 
alendronate may not have the same tolerability and efficacy as branded alendronate in the first 
weeks after starting treatment in patients with a recent fracture. Patients who were previously 
stable on doses of brand alendronate experienced an increase in adverse events causing 
discontinuation after introduction of automatic substitution to generic alendronate (17). 
In Pakistan, currently multiple pharmaceutical formulations containing alendronic acid are 
manufactured and marketed by many local pharmaceutical companies with varied prices and 
may differ in their quality towards the innovator product (18). In line of this, the objectives of the 
present study were to conduct in-vitro and in-vivo studies of oral formulations of alendronate 
sodium 70mg.  The research was conducted according to standard specifications of United States 
Pharmacopoeia (USP) and an open-label, randomized, two-period cross over comparison in 
Pakistani male adult volunteers was done to compare bioavailability and pharmacokinetic 
parameters (PK) of leading brands with generic product. This study will help the policy makers 
in guiding various Government and private institutions to buy good quality and cheap generic 
alendronate sodium in order to cater the demands of patients suffering from osteoporosis and will 
also save a lot of foreign exchange incurred on medicines. It will also help boosting the 
confidence of the medical professionals to prescribe locally manufactured drugs and also aid the 
local industry to export to neighboring countries to earn foreign exchange as well. 
 
2. Subjects and Methods 
2.1 In-Vitro Analysis 
A total of ten leading brands of alendronate sodium 70mg tablets available in the market were 
purchased, i.e., brand leader and generic; and were tested according to standard USP methods. 
The samples were tested for their in-vitro characteristic, i.e., physical and chemical parameters, 
disintegration time and dissolution percentage (19). In-vitro tests were performed according to 
USP30 guidelines. The dissolution test was performed by Paddle method (dissolution apparatus 
ERWEKA DT6, GmbH, Germany) with following parameters: water as medium; speed 50rpm; 
dissolution medium volume 900ml, time 15min, temperature 37.0 ± 0.5oC. Disintegration test 
(ERWEKA ZT3-A, GmbH, Germany) was also performed according to the specifications of 
USP30.  
Assay for to quantify alendronate was conducted based on USP monograph for alendronic acid 
tablets. Alendronic acid tablets contain an amount of alendronate sodium equivalent to 90-110% 
of the labeled amount. Briefly, after mixing standard/test solution with sodium citrate dihydrate 
diluent and borate buffer for 3min, 0.05% 9-fluorenylmethyl chloroformate solution was agitated 
with previous mixture for 30 seconds. The resultant mixture was allowed to stand for 25min at 
room temperature and then centrifuged after adding methylene chloride for 5min. Upper layer 
was analyzed by high performance liquid chromatographic (HPLC) and amount of alendronate in 
test/standard sample was estimated by comparing the chromatogram peaks of respective samples 
with calibration standards. Same method was used to determine percentage of active in 
dissolution test (19).  
2.2 In-Vivo Analysis 
2.2.1 Study Design 
In-vivo studies were materialized through open-label, randomized, 2-sequence, 2-period 
crossover study in healthy male adult population to compare their bioavailability and PK 
parameters of the brand leader with generic product. The studies were carried out at Drugs 
Control and Traditional Medicines Division (DCTM), National Institute of Health (NIH), 
Islamabad, Pakistan.   
2.2.2 Subjects 
Healthy Pakistani adult male subjects were eligible to be enrolled in the study. Inclusion criteria 
consisted of unremarkable results on medical history, physical examination, and clinical 
laboratory tests (vital signs, serum chemistry and hematology, and urinalysis). Subjects with HIV 
or hepatitis B were excluded from the study. Concurrent medications and the consumption of 
alcohol were not allowed from 2 weeks before administration of the first dose until the end of the 
study period. Subjects were informed about the aims and risks of the study, and written informed 
consent was obtained from all volunteers before screening. The study protocol was approved by 
the board of studies of Sargodha University, Sargodha, Pakistan and DCTM, NIH, Islamabad, 
Pakistan. All protocols were in accordance with the revised Declaration of Helsinki (20) and the 
Good Clinical Practice guidelines (21). All the drugs used for bioequivalence studies were 
procured from market and reference standard of alendronate sodium for the study was provided 
by M/S MSD (OBS), Pakistan. All chemicals used in the study were from Sigma/Merck 
(analytical or HPLC grade). Distilled water was used wherever required in the study.  
2.2.3 Blood sampling and sample processing  
24 healthy adult male volunteers were randomly assigned to receive a single 70mg dose of test or 
reference formulation of alendronate sodium, administered with 240ml of water, followed by a 7 
day washout period and subsequent administration of alternate formulation. Drugs were 
administered after 12 hour overnight fast. Serial blood samples were collected and adverse 
events, if any, were monitored by a clinical investigator via observation, personal interview, and 
measurement of vital signs (blood pressure, heart rate and body temperature) over a 7h period (at 
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 7 hours) after drug administration. After collection, the 
blood sample was immediately centrifuged (Cat. No. 9527-16, Abbott Diagnostics Centrifuge 
machine) at 4000rpm for 15min and separated plasma was frozen (UNI-TRAP UT-50L 
refrigeration system) at -Û&in eppendorf tubes until analysis. 
Plasma alendronate sodium concentrations were determined using a validated HPLC-post 
column fluorescence derivatization method, with visible detection in the range of 2 to 100 ng/ml 
and lower limit of quantification set at 2 ng/ml (22, 23). PK properties including AUC0-t, AUC0-
, Cmax, Tmax, t1/2, and the elimination constant (ke) were determined by non-compartmental 
analysis. The formulations were considered bioequivalent if 90% CI ratios for Cmax and AUC 
were within predetermined interval of 80% to 125% that is the regulatory definition set by US 
Food and Drug Administration (24). 
2.2.4 Standard curve 
Stock solution of alendronate sodium in a concentration of 1mg/ml was prepared in mobile phase 
(buffer solution: acetonitrile: methanol, 75: 20: 5). The stock solution was then diluted to 
100µg/ml with methanol to make a working stock solution. From this working stock solution, 
calibration standards were prepared in plasma in concentrations of 1, 2, 3, 4, 5, 6, 7, 9, 10, 12 and 
15µg/ml (Figure 1). 
2.2.5 Extraction and assay of alendronate from plasma 
Stored frozen plasma was thawed and 200µg of plasma was vortexed (Model MA-1, Torika) 1ml 
methanol in eppendorf tube for 2 minutes. The sample was then centrifuged (Cat. No. 9527-16, 
Abbott Diagnostics Centrifuge machine) at 10000rpm for 10 minutes and 800µl of the 
supernatant was separated in another tube. The sample was dried in a vacuum oven (VOS-300, 
EYELA) and the residue left after drying was reconstituted with 200µl of mobile phase that was 
composed of buffer solution (14.7g Sodium citrate dihydrate and 7.05g anhydrous disodium 
hydrogen phosphate, pH 8) acetonitrile, and methanol in ratio 75: 20: 5. 100µl of sample was 
injected into the HPLC system (LC-9A; Column: L-21, 4.1 x 250mm, 5µ particle size; 
temperature 350C) for analysis (19). Mobile phase was set to flow through sample at the rate of 
1ml/min. Analyte detection was done with a Fluorescence detector (LC 9A, Shimadzu, Japan). 
The fluorometric detector was operated at 260 nm (excitation) and 310 nm (emission). Amount 
of alendronate in plasma was estimated from calibration curve by recording the chromatogram 
and measuring the responses for the major peaks. 
2.2.6 Pharmacokinetic and Statistical Analysis 
A non-compartmental pharmacokinetic model was used to determine the pharmacokinetic (PK) 
parameters of alendronate sodium. The PK parameters i.e., AUCĺt, AUCĺ, Cmax, Tmax, t1/2 
were determined using Minitab® 16 (Minitab, Inc., USA) for each of the volunteers for both the 
drugs. Both the AUC and AUMC were calculated using the trapezoidal rule, more specifically 
the AUMC was calculated by constructing the area under the concentration (C) times time (T) 
versus time (T) curve (C.T vs. T). The mean residence time (MRT) for the drugs was calculated 
as MRT = AUMC/AUC. Statistical comparisons between pharmacokinetic parameters of the two 
products were analyzed by two-way ANOVA with p < 0.05 for statistical significance. Data was 
presented as mean±SD of multiple values. 
The first-order terminal elimination rate constant (Kel) was determined by linear regression 
using points describing the elimination phase on a log-linear plot. The Cmax and Tmax 
parameters were obtained directly from the curves. The areas under the curve for alendronate 
plasma concentration versus time for 0±t (AUC0-t) were calculated by applying the linear 
trapezoidal method. 
 The 90% confidence intervals of the test/reference ratio of Cmax, AUC0ĺt and AUCĺ were 
determined using log transformed data. The bioequivalence between the two formulations was 
accepted if 90% CI of the log transformed Cmax, AUC0ĺt and AUCĺ of test was within 80-
125% of the original product (19).  
 3. Results 
3.1 In-Vitro Parameters 
The chemical assay, disintegration time and dissolution rate of all test brands were found within 
the specifications of USP (Table 1). The brand leader FOSAMAX® from MSD, Pakistan and the 
one having best dissolution rate were selected for bioequivalence studies.  
3.2 In-Vivo Parameters 
Among the 24 volunteers enrolled in the study, no serious adverse event was found throughout 
the study period. There was insignificant difference in all analyzed pharmacokinetic parameters 
among all brands of alendronate sodium. The demographic parameters of subjects were as 
follows: mean age 23.5±3.5 years (range 21±29 years); mean height 175.4±3.8cm (range 152.0±
173.0cm); and mean weight 68±4.8kg (range 64±76 kg). 
3.2.1 Alendronate sodium quantification in plasma 
The analytical method for alendronate sodium quantification in plasma samples had good 
specificity, sensitivity, linearity, precision, and accuracy over the entire range of clinically 
significant and therapeutically achievable plasma concentrations, thereby enabling its use in 
bioequivalence trials. The linearity was observed within the range of 1 to 100 ng/ml (alendronate 
sodium; y = 45579x + 21172, r2 = 0.988; x = plasma concentration, y = peak area ratio) (Figure 
1). The intra-day precision ranged from 0.29% to 1.78%, whereas intra-day accuracy ranged 
from 97.9% to 100.9%. Inter-day precision ranged from 0.82% to 1.56%, whereas inter-day 
accuracy ranged from 98.30% to 102.6%. The amount extracted of alendronate sodium was 
determined in pentaplicates. The mean absolute recovery was 92.82%, whereas the relative 
recovery ranged from 94.9% to 101.2%. 
Pharmacokinetic parameters were determined from the plasma level-time curve drawn for either 
of the drugs in each volunteer (annex.1), . The results of ANOVA revealed that Cmax, ln Cmax, 
Tmax, AUC, ln AUC0-t, AUC0-, and ln AUC0- were statistically insignificant for effect subject, 
period and treatment. Statistical analysis of the pharmacokinetic parameters of the test and 
reference drug are presented in table 2. The geometric mean ratio (90% CI) of these parameters 
along with the results of bioequivalence test are presented in table 3. Since, 90% CI for all 
parameters was within the predefined bioequivalence acceptance limits (80-125% of the 
originator); therefore, the test and reference formulations were considered bioequivalent. Hence, 
Osteopor® could be concluded as having comparable pharmacokinetic profiles with Fosamax®. 
3.2.2 Tolerability 
Both formulations of alendronate sodium 70mg were well tolerated by all volunteers. No clinical 
undesirable events were observed throughout the study and for up to two week after the study. 
Table 1: In-vitro analysis of various brands of alendronate sodium (70mg) 
 
S. No. 
Brand 
(70mg) 
Manufacturer 
Batch 
No 
Mfg 
Date 
Expiry 
Date 
Avg. Wt % Assay 
Amount of 
active 
substance 
(mg) 
D-Time 
(min) 
% 
Dissolution 
1 BONAFIDE Medisure 004 12/12 12/14 
0.330 
±0.21 
95.6 66.92 11  81.4 
2 BONATE Wilshire 007 9/11 8/13 
0.216 
±0.14 
96.6 67.6 13 80.1 
3 BONGARD PharmEvo 9N033 12/09 12/11 0.205±0.26 101.7  71.2  11 86.6 
4 FOSAMAX OBS Pharma 
NM 
22110 
10/09 10/12 0.746±0.42 100.2 70.1 12 90.2 
5 ORTHONATE Schazoo 
Ont 
013 
Jan, 2012 
Jan 
2014 
0.442±0.09 100.3 70.21 8 
 
82.4 
 
6 OSTEOPOR Werrick 1414 12/09 12/11 0.553±0.24 101.7 71.2 10 94.4 
7 REVENTA-70 Getz 
051T 
24 
12/12 12/14 0.201±0.18 101.5 71.05 8 88.6 
8 ALENDRATE Global 051 01/12 01/14 0.335±0.06 101.7 71.19 2 80.6 
9 OSTIM Genome 003 05/12 05/14 0.445±0.18 100.1 70.07 7 84.8 
10 DRATE 
SJG Fazal 
Ellahee 
2251T 08/12 08/12 0.566±0.12 99.7% 69.8 
9 82.6 
D-Time = disintegration time; average weight of tables is expressed in mean±SD. % active is determined with assay limit of 90-110%. Dissolution assay limit is 80%. All tests are according to USP.
 
 
 
Table 2. Statistical analysis of pharmacokinetic parameters for test and reference drug in 1st and 2nd periods. 
Pharmacokinetic Profile 
Statistical Analysis 
Test Drug Reference Drug 
Mean SD SE Min Max Mean SD SE Min Max 
AUC0-t (ng.hr/ml) 112.17 8.26 1.72 99.00 131.00 116.39 6.97 1.45 105.00 131.00 
AUC0-inf (ng.hr/ml) 117.09 17.65 3.68 73.00 150.00 119.04 9.05 1.89 105.00 137.00 
Ke (l/h) 0.25 0.11 0.02 0.10 0.57 0.37 0.16 0.03 0.11 0.75 
MRT (h) 2.78 0.55 0.11 1.90 3.50 2.66 0.82 0.17 0.97 3.78 
t1/2_e (h) 1.92 0.61 0.13 0.81 3.08 1.85 0.45 0.09 1.19 2.83 
Cmax (ng/ml) 49.5 6.86 1.43 41.47 67.7 58.22 8.98 1.13 43.87 79.99 
Tmax (h) 1.00*   0.75 1.5 1.00*   0.75 1.5 
AUC= area under curve; ke= elimination rate constant; MRT= mean residence time; t1/2_a= absorption half life; Cmax= maximum plasma concentration; Tmax= time to reach maximum plasma 
concentration; *median values were calculated 
 
 
 
 
 
Table 3. Pharmacokinetic parameters of test and reference drugs. 
Parameter Test Reference 
Standard Observed Within Equivalent Limit 
Lower Upper Lower Upper Lower Upper 
ln AUC0-t (h.ng/ml) 4.72 ± 0.07 4.75 ± 0.10 80% 125% 0.967 1.04 Yes Yes 
ln AUC0-inf (h.ngm/l) 4.72 ± 0.04 4.78 ± 0.09 80% 125% 0.969 1.04 Yes Yes 
ln Cmax (ng/ml) 3.90 ± 0.07 4.06 ± 0.08 80% 125% 0.962 1.06 Yes Yes 
         
 
 
  
 
 Figure 1: AUC standard curve for alendronate sodium 
 Figure 2. Plasma concentration-time plots of alendronate Sodium. The plot is obtained after a single oral dose (70mg) of reference 
and test formulation in healthy volunteers (N=24). No statistical significant difference was recorded. Data is presented as mean values. 
 
 
 
 
 
 
4. Discussion 
The appearance of off-patent generic drugs in the world¶V pharmaceutical market is a highly 
interesting fact from the socio-economic point of view and can bring about an increased 
efficiency in health systems and increase the percentage of population benefitting from a medical 
care plan (25). The World Health Organization has reported various copies of substandard 
quality of original pharmaceutical products (26). The substandard drugs contain low quality 
ingredients or lack the specified ingredient altogether. Moreover, even when the definite 
ingredient is present, in some cases, it does not dissolve satisfactorily or the amount is improper 
(27). It was recognized some 50 years ago that unless an oral dosage form (pill or tablet) 
disintegrates into small aggregates, it can not be efficiently absorbed by the body (28). However, 
a switch from disintegration testing to dissolution testing is due to the fact that only tablet 
disintegration does not ensure its availability in solution form for absorption. Today, 
disintegration is typically conducted as an in-process test during tablet manufacture. Thus, in 
present study, dissolution and disintegration tests of all brands of alendronic acid tablets 
analyzed were rapid, complete and conformed to the established USP30 specifications (Table 1) 
ensuring adequate drug absorption from the generic products. However, the generic products of 
alendronic acid tablets are approved based on the results of single-dose bioavailability studies in 
healthy subjects which is not an adequate test to establish similar disintegration characteristics 
(29). In United States, if a drug substance and a drug product monograph exist in USP, the 
generic version is expected to conform to these established quality specifications. The generic 
version is also required to use the same salt form of the active ingredient, as the salt form can 
affect the inherent solubility and subsequent absorption of the active ingredient. Thus, alendronic 
acid must also be formulated as sodium salt. There is currently a USP monograph for alendronate 
sodium (active substance) and for alendronic acid tablets (19) and unless stated otherwise the 
generic form should conform to these standards. In our study, all generics and brands tested 
conformed to USP standards (Table 1). Recently, a study has shown that for all drug categories 
investigated, the patients who experienced a generic switch did not have more concerns about 
their index medicine than patients who did not switch and patients having high con¿dence in the 
health-care system showed less concern (30). 
Generic versions of alendronate have been reported to be bioequivalent to branded alendronate 
(22, 23). The development of a brand name formulation requires the demonstration of its 
pharmacokinetics, efficacy and tolerability in both healthy subjects and in the target patient 
population. However, the development of the generic equivalent requires only the demonstration 
of its bioequivalence with the brand name product in healthy subjects (31). WHO guidelines 
state that 18 to 24 healthy male and female volunteers aged 18 to 55 years of normal body weight 
should be used in a crossover study design to determine whether bioequivalence is achieved 
between two formulations (21). It is assumed that bioequivalence demonstrated in crossover 
studies performed in this typically younger and healthier population would be equivalent to that 
observed in the patient population. It is further supposed that this bioequivalence would translate 
into comparable clinical efficacy and tolerance; however, evidence to support the existence of a 
well-defined relationship between these parameters is lacking (32). These differences have 
fostered concern as to whether bioequivalence, as ascertained in crossover studies of healthy 
adults, should be used to make claims of comparable clinical effectiveness and tolerability in 
patients who are older and often have numerous underlying disorders or diseases. Further, older 
individuals tend to have greater difficulty in swallowing pills (orientation of pill in mouth) and 
have reduced GI motility as compared to younger individuals. These differences may increase 
the exposure time of the alendronate tablet to the upper GI tract which could then increase the 
probability of alendronate exposure to the esophagus in older adults.  
Much dissimilarity exists between brand and generic alendronate including: disintegration time, 
bio-adhesion to the esophagus, patient compliance to treatment, adverse event prevalence, and 
conservation of bone mineral density. Generic forms of alendronate warrant closer clinical study 
before their credibility for clinical usefulness and acceptability of brand. Differences in the 
excipient composition between the brand and generic formulations of alendronate may alter the 
bioavailability of the generic alendronate to bone if this substitution changes the behaviour of the 
tablet such that the alendronate tablet becomes more easily bound to food or drink and 
unavailable for absorption in the gut (33). 
Since, the bioavailability of alendronate is low and dosing requirements are strict; therefore, any 
characteristic of the tablet that changes the speed of delivery of alendronate, such as time 
required for disintegration or dissolution, can have important implications on drug effectiveness 
or tolerance. For regulatory approval, explicit dissolution parameters are required to allow for the 
generic substitution of brand alendronate; however, there are no specifications for the required 
disintegration characteristics of the generic forms.  
It has been reported (29) that the dissolution and disintegration rates of a number of generic 
formulations of alendronate from Canada, Netherlands, Germany, and United Kingdom were 
compared to United States manufactured brand risedronate and alendronate. All of the generics 
tested had an acceptable dissolution rate as compared to brand alendronate. Commercially 
available oral tablets designed to dissolve in mouth without water prior to swallowing were 
purposefully included to act as disintegration comparators. Six of the 26 generic versions of 
alendronate tested had disintegration times that were comparable to oral tablets disintegrating in 
mouth.  
Furthermore, substantial evidence indicates that many generic formulations of alendronate are 
more poorly tolerated than the proprietary preparations resulting in ominously poorer adherence 
and efficacy (34). Reduced effectiveness may result from faster disintegration times of many 
generics that increase the likelihood of adherence of particulate matter to the esophageal mucosa. 
Unfortunately, market authorisation, based on the bioequivalence of generics with a proprietary 
formulation, does not take into account the potential concerns about safety. Poor adherence of 
many generic products has implications for guideline development, cost-effectiveness and 
impact of treatment on the burden of disease. The impact of generic bisphosphonates requires 
formal testing to re-evaluate their role in the management of osteoporosis. 
The majority of generic versions of alendronate disintegrate faster or slower than brand 
alendronate, whereas dissolution times are largely similar between brand and generic 
alendronate. Moreover, a qualitative study had shown two general themes: first, complications in 
recognizing the substituted medicine and second, ODFNRIFRQ¿GHQFHLQWKHLGHQWLFDOHIIHFWRIWKH
substitutable medicines (35). Previous interview and questionnaire based analysis have shown 
that some patients felt anxious and insecure about generic substitution and furthermore expressed 
uncertainty with regard to inferior quality of the generic drugs compared with the original 
products. Moreover, side effects were experienced by some users of generic drugs (35, 36, 37). 
The Drug Regulatory Authority (DRAP) of Pakistan has not made it mandatory requirement for 
marketing a generic in Pakistan with bioequivalence studies, nevertheless, bioequivalence studies 
have been carried out in recent years either for the purpose of quality enhancement or as a 
marketing tool (38, 39). We are aware of the fact that there are strict guidelines in Europe and 
USA for marketing authorization of oral (small molecule) generics to ensure good quality and 
enhance their utilization. This is recognized as the first step to enhance the use of generics versus 
originators and patented products in a class. Without such legislation and subsequently its 
implementation in its true letter and spirit, there will always be concerns with the quality of 
generics especially the one that are locally produced. It will also be difficult to promote low 
priced generics in Pakistan. There is a dire need to revisit the drug policy of DRAP to promote 
and encourage the prescribing of low cost generics with highest quality, especially with generics 
priced at 2% to 10% of pre-patent loss prices as established in some (5, 6, 40). Our study is a 
step towards this goal.  
5. Conclusions 
It is concluded that in the present study in healthy male Pakistani volunteers, no statistically 
significant differences in AUC0±t, AUC0±, and Cmax were found between the test and reference 
formulations of alendronate sodium. The single 70-mg dose of these formulations met the 
regulatory criteria for bioequivalence and all test brands were within the acceptable quality 
limits.  
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